Compare BridgeBio Pharma Inc (BBIO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Incyte Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap. Which is the better fit depends on your goals.
| BBIO | INCY | |
|---|---|---|
Market Cap | $16.36B | $24.54B |
Sector | Health | Health |
52-Week High | $90.17 | $129.93 |
52-Week Low | $47.29 | $81.61 |
Enterprise Value | $18.14B | $20.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
